Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in moderate-to-severe atopic dermatitis
NCT02525094Phase 2Completed
- Sponsor
- MedImmune
- Start
- Aug 2015
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of tezepelumab in atopic dermatitis (AD), sponsored by MedImmune. Started Aug 2015; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02525094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525094.